People wait to receive their second dose of COVISHIELD outside a vaccination centre in Kolkata, India.
India began an inoculation drive for its 1.38 billion people in earnest in mid-January.
Healthcare, frontline workers and the elderly were the first eligible, followed by people aged over 45 in April and then adults aged 18-45 in May.
That last extension, covering around 43% of the population, proved to be a crunch point.
Following a surge in COVID-19 infections across the country in April, Prime Minister Narendra Modi accelerated plans to broaden the programme and opened up vaccinations from May 1 for people aged between 18 and 45 years.
READ MORE
Billionaire Bill Gates on trial over Covid-19 vaccines safety
Scientists urge nations to prepare for pandemic by voting wisely
About 400mln people worldwide have had long Covid-19, research
The decision led to a rush by people in that age group, who account for 600 million of the population, to sign up to the government’s CoWIN vaccination website. Critically, there was no corresponding increase in vaccine supplies.
By June 4, India had provided at least one dose to roughly 50 million people aged between 18 and 44, representing just 8% of that population group.
Adding to the difficulties, a privilege gap emerged in the vaccination rollout, with hospitals charging different prices for the same vaccine. Some hospitals in affluent areas have sold the Covishield shot, manufactured in India, for 1,800 rupees ($25) a dose, almost double the 950 rupees charged elsewhere.
3D-printed small toy figurines, a syringe and vial labelled "coronavirus disease (COVID-19) vaccine".
Also, urban Indians have received shots faster than those living in the countryside. That means vaccines remain unavailable to a large part of the population that cannot afford it or has little or no access to private hospitals.
Vaccine importer
India - the world's biggest producer of vaccines for polio, diphtheria and other diseases - sold or donated more than 66 million COVID-19 vaccine shots to 95 countries until the middle of April.
But as infections started rising from around mid-March in India, the clamour for vaccines at home also increased. India has now started importing vaccines and also expecting donations from the United States.
The government expects vaccine supplies to improve substantially from June. It is expecting to produce enough shots by December to inoculate all of its estimated 950 million adults, though those between 18 and 45 years will be the last on the priority list.
Several states in India have begun to gradually lift restrictions on travel and businesses, after a fall in cases in recent weeks. However, health experts have warned that cases could surge again once most states re-open, and have called for vaccinations to be sped up.
As of June 8, less than 4% of India’s adult population had been given the required two vaccine doses. Nearly 14% received at least one dose and, of that group, less than one-tenth of 18-45-year-olds have been inoculated.
